Teleflex (TFX) AI Stock Analysis

• Market Cap: $5.61B
• Dividend Yield: 1.07%
• Average Volume (3M): 656.76K
• Price to Earnings (P/E): 40.0
• Beta (1Y): 0.74
• Revenue Growth: 0.29%
• EPS Growth: -48.98%
• Country: US
• Employees: 14,100
• Sector: Healthcare
• Sector Strength: 44
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 2.91
• Shares Outstanding: 44,188,984
• 10 Day Avg. Volume: 489,467
• 30 Day Avg. Volume: 656,757
• PEG Ratio: 0.32
• Price to Book (P/B): 1.40
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 11.52
• Enterprise Value/Market Cap: 1.29
• Enterprise Value/Revenue: 0.60
• Enterprise Value/Gross Profit: 4.32
• Enterprise Value/Ebitda: 3.28
• 1Y Price Target: $149.71
• Price Target Upside: 22.74% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 11

• Rating: 58 Neutral
• Price Target: ―

Teleflex's solid financial performance is offset by technical indicators pointing towards bearish sentiment and perceived overvaluation. Strategic initiatives and acquisitions offer potential long-term growth, but near-term challenges such as revenue declines and operational pressures weigh down the outlook.

Positive Factors

Acquisition interest

TFX has started to engage potential buyers for NewCo, and the interest in acquiring NewCo is described as significant, validating the separated businesses as good assets.

Earnings performance

TFX reported Q1 results that beat both consensus and analyst estimate on EPS.

Shareholder value

The separation will reduce the number of RemainCo manufacturing facilities to 7 from 19 as a combined company, simplifying the business and unlocking shareholder value.

Negative Factors

Financial performance

An underperform rating is maintained due to limited growth visibility and ongoing challenges facing TFX.

Revenue growth

Management lowered GM and OM guidance for the year.

Tariff impact

The tariff situation is too volatile, and TFX is not updating its guidance, indicating uncertainty in future financial impacts.

Teleflex Business Overview & Revenue Model

Company Description

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site. The company also offers interventional products, which consists of various coronary catheters, structural heart therapies, and peripheral intervention and cardiac assist products that are used by interventional cardiologists and radiologists, and vascular surgeons; and Arrow branded catheters, Guideline and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices. It provides anesthesia products, such as airway and pain management products to support hospital, emergency medicine, and military channels; and surgical products, including metal and polymer ligation clips, and fascial closure surgical systems that are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments. The company also offers interventional urology products comprising the UroLift System, an invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia; and respiratory products, including oxygen and aerosol therapies, spirometry, and ventilation management products for use in various care settings. It provides urology products, such as catheters, urine collectors, and catheterization accessories and products for operative endourology; and bladder management services. The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets. The company was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.

How the Company Makes Money

Teleflex generates revenue primarily through the sale of its medical devices across multiple healthcare sectors. The company's key revenue streams include the Vascular Access segment, which offers catheters and access devices; the Anesthesia segment, which provides airway management and pain management products; and the Surgical segment, which includes ligation, closure, and other surgical products. Teleflex also earns income through its Interventional segment, focusing on cardiac care and urology products, and its OEM and Development Services segment, which develops and manufactures products for third-party medical device companies. The company's earnings are bolstered by strategic acquisitions that expand its product offerings and market presence, as well as partnerships with healthcare providers and institutions that enhance its distribution network.

Teleflex Financial Statement Overview

Summary

Teleflex exhibits strong financial health with robust cash flow management and stable balance sheet metrics. Profitability is strong, though there are some operational cost challenges as reflected in the lower EBIT margin.

Income Statement

Teleflex shows strong profitability with a Gross Profit Margin of 55.7% and Net Profit Margin of 5.0% in TTM. Revenue grew modestly at 0.6% from the previous year, indicating stable growth. Notably, the EBITDA Margin stands at 15.9%, reflecting healthy operational efficiency. However, the EBIT Margin is somewhat lower at 8.6%, suggesting some operational cost challenges.

Balance Sheet

The company maintains a solid financial structure with a Debt-to-Equity Ratio of 0.05, indicating low leverage. The Return on Equity is 3.6% in TTM, which is moderate but could be improved. The Equity Ratio is robust at 57.2%, showcasing a strong equity base. Overall, the balance sheet is stable with manageable debt levels.

Cash Flow

Teleflex exhibits strong cash flow management, with a Free Cash Flow to Net Income Ratio of 3.41 in TTM, indicating efficient cash generation relative to earnings. The Operating Cash Flow to Net Income Ratio is 4.00, highlighting strong cash conversion. Free Cash Flow has grown slightly by 0.2% from the previous year, maintaining positive cash flow growth.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
3.01B	3.05B	2.97B	2.79B	2.81B	2.54B
	Gross Profit
1.68B	1.70B	1.65B	1.53B	1.55B	1.32B
	EBIT
290.63M	151.01M	506.31M	499.73M	628.10M	423.07M
	EBITDA
479.36M	452.66M	761.21M	751.65M	873.10M	665.98M
	Net Income Common Stockholders
149.39M	69.67M	356.33M	363.14M	485.37M	335.32M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
284.12M	290.19M	222.85M	292.03M	445.08M	375.88M
	Total Assets
7.16B	7.10B	7.53B	6.93B	6.87B	7.15B
	Total Debt
2.00B	1.76B	1.93B	1.83B	1.97B	2.56B
	Net Debt
1.72B	1.46B	1.70B	1.54B	1.52B	2.19B
	Total Liabilities
3.07B	2.82B	3.09B	2.91B	3.12B	3.82B
	Stockholders Equity
4.10B	4.28B	4.44B	4.02B	3.75B	3.34B
Cash Flow		Free Cash Flow
479.84M	509.31M	419.20M	262.95M	579.80M	345.71M
	Operating Cash Flow
597.85M	635.74M	510.64M	342.14M	651.42M	436.41M
	Investing Cash Flow
-103.34M	-99.36M	-621.23M	-257.94M	156.74M	-837.78M
	Financing Cash Flow
-350.48M	-421.93M	38.54M	-217.51M	-715.82M	455.16M

Teleflex Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 121.97
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TFX, the sentiment is Negative. The current price of 121.97 is below the 20-day moving average (MA) of 127.90, below the 50-day MA of 132.17, and below the 200-day MA of 184.79, indicating a bearish trend. The MACD of -2.26 indicates Negative momentum. The RSI at 39.40 is Neutral, neither overbought nor oversold. The STOCH value of 35.62 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TFX.

Teleflex Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MMSI	76 Outperform	$5.84B	47.32	9.16%	―	8.24%	18.54%
HAE	69 Neutral	$3.46B	20.18	18.83%	―	8.14%	2.55%
ICUI	68 Neutral	$3.32B	―	-4.62%	―	7.19%	-56.19%
TFX	58 Neutral	$5.61B	39.98	3.48%	1.07%	0.29%	-48.98%
BLCO	57 Neutral	$4.15B	―	-5.56%	―	11.94%	-6.98%
RGEN	56 Neutral	$7.17B	―	-1.16%	―	4.88%	-196.93%
Sector *	53 Neutral	$5.24B	3.07	-43.58%	2.80%	16.87%	-0.11%

Teleflex Corporate Events

Teleflex Amends Bylaws to Ease Stockholder Actions

On May 9, 2025, Teleflex Incorporated’s Board of Directors approved amendments to the company’s bylaws, specifically removing a section that required stockholder actions to occur only at official meetings. This change could impact how stockholder decisions are made in the future. Additionally, during the 2025 annual meeting, stockholders voted on various proposals, including the election of directors and executive compensation, with most proposals receiving majority approval, except for a stockholder proposal on special meeting requirements.

The most recent analyst rating on (TFX) stock is a Buy with a $285.00 price target. To see the full list of analyst forecasts on Teleflex stock, see the TFX Stock Forecast page.

Teleflex Raises Revenue Outlook Amid Q1 Revenue Decline

Teleflex reported a decrease in first-quarter revenues for 2025, with a 5.0% decline compared to the previous year, and adjusted diluted EPS also fell from $3.21 to $2.91. Despite these challenges, the company raised its full-year revenue growth outlook on a GAAP basis and completed a $300 million accelerated share repurchase. Teleflex is also exploring the separation into two independent companies, which has attracted significant third-party interest. The company is working on strategies to mitigate the impact of tariffs, which are expected to cost approximately $55 million in 2025.

Teleflex Announces CFO Change and Strategic Split

On February 24, 2025, Teleflex amended its credit agreement to facilitate a $500 million delayed draw term loan for acquiring BIOTRONIK’s Vascular Intervention business, enhancing its product suite in coronary and peripheral interventions. Additionally, the company announced the retirement of CFO Thomas E. Powell and the appointment of John R. Deren as his successor, effective April 2, 2025, alongside strategic plans to separate into two publicly traded entities, aiming to streamline operations and increase management focus.